<DOC>
	<DOCNO>NCT02533102</DOCNO>
	<brief_summary>This study design first evaluate effect food E7050 's pharmacokinetic parameter follow administration single 100 mg oral dos E7050 tablet normal healthy participant study ( Part A ) , second characterize E7050 pharmacokinetics single dos 200 mg 400 mg fast condition ( Part B ) . Part A randomized , single-dose , open-label , three-treatment period crossover study . Part B nonrandomized , open-label , two-treatment sequential study design . Twelve participant Treatment Period 1 receive single dose 200 mg E7050 fast condition . Following review safety data 200 mg dose level , additional 12 subject receive single dose 400 mg E7050 Treatment Period 2 .</brief_summary>
	<brief_title>Pharmacokinetics Food Effect Single Oral Dose E7050 Healthy Volunteers</brief_title>
	<detailed_description />
	<criteria>Inclusion criterion : Subjects must meet follow criterion include study : 1 . Normal healthy adult male female ( age 1845 year ) . 2 . Body Mass Index ( BMI ) great equal 18 less equal 32 time Screening . 3 . Pregnancy lactation . Female patient childbearing potential must negative pregnancy test inclusion study , must agree use medically acceptable method contraception ( eg , abstinence , condom + spermicide , doublebarrier method [ eg , condom + diaphragm spermicide ] , intrauterine device ( IUD ) , vasectomised partner ) start Screening throughout entire study period 2 month last dose study drug . Those female patient use hormonal contraceptive must also use additional approve method contraception ( describe previously ) start Cycle 1 Day 1 , continue throughout entire study period 2 month last dose study drug . Postmenopausal woman must amenorrheic least 12 consecutive month ; otherwise pregnancy test require . Male patient must agree use contraceptive method ( eg , abstinence , condom + spermicide doublebarrier method [ eg , condom + partner diaphragm spermicide ] ) . 4 . Nonsmokers . 5 . Willing able comply aspect protocol . 6 . Provide write informed consent . Participants meet follow criterion exclude study : 1 . Evidence clinically significant cardiovascular , hepatic , gastrointestinal , renal , respiratory , endocrine , hematological , neurological , psychiatric disease abnormality know history gastrointestinal surgery could impact pharmacokinetics study drug . 2 . Clinically significant illness within 8 week clinically significant infection within 4 week dose . 3 . Evidence organ dysfunction clinically significant deviation normal medical history . 4 . Evidence clinically significant deviation normal physical examination , vital sign , clinical laboratory determination Screening Baseline . 5 . An interval correct heart rate ( QTcF ) interval great 450 msec Screening Baseline . 6 . Females either pregnant lactating . 7 . A known suspected history drug alcohol abuse within 6 month prior screen , positive urine drug test alcohol test Screening Baseline . 8 . Positive result Hepatitis B surface antigen ( HBsAg ) Hepatitis C antibody ( HCV ) screen . 9 . Diagnosis acquire immune deficiency syndrome ( AIDS ) , positive test human immunodeficiency virus ( HIV ) . 10 . Participation another clinical trial le 4 week prior dose current enrollment another clinical trial . 11 . Receipt blood product within 4 week , donation blood within 8 week , donation plasma within 1 week prior dose . 12 . Hemoglobin level le 12.0 g/dL . 13 . Known history significant drug food allergy ongoing seasonal allergy . 14 . Use prescription drug within 2 week prior Screening ( unless drug long t1/2 , ie , 5 x t1/2 exceed 2 week ) . 15 . Use overthecounter ( OTC ) medication within minimum 2 week prior dose . 16 . Requiring special diet take dietary aid know modulate drug metabolize enzyme , consume foods/beverages herbal preparation contain Kava root , Ginkgo Biloba Extract ( GBE ) , St. John 's Wort within 4 week Baseline Period 1 . 17 . Known intolerance study drug ( excipients ) . 18 . Any medical condition , opinion investigator , would preclude participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>Pharmacokinetics</keyword>
	<keyword>E7050</keyword>
	<keyword>Healthy Subjects</keyword>
</DOC>